Pulmonary Arterial Hypertension (PAH) research hub
7 indexed studies · 1 currently recruiting
- ongoing, recruitingPhase II and Phase III (Integrated)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is looking into a new treatment, AV-101, for Pulmonary Arterial Hypertension (PAH), a condition affecting the lungs and heart. It aims to see if the treatment is safe and effective by comparing it to a dummy medicine.
Czechia · Ireland · Poland - ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Portugal · Italy · Sweden - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ADVANCE Outcomes)
This study is looking at a new medicine called Ralinepag for a lung condition called pulmonary arterial hypertension (PAH). It wants to see if Ralinepag can help patients feel better and prevent their condition from getting worse over time.
Hungary · Belgium · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo_Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality
This study is testing a new medicine, sotatercept, for adults with severe pulmonary arterial hypertension (PAH). Researchers want to see if adding sotatercept to existing treatments can prolong life, prevent lung transplants, or reduce hospital stays related to PAH worsening.
Belgium · Netherlands · Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
This study is looking at a new medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Researchers want to see how the body handles the medicine and check for any side effects. It’s a randomised study, meaning some people will get different doses.
Czechia · Poland · Spain - recruitingPHASE2
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is looking at a new experimental drug, REGN13335, for adults with Pulmonary Arterial Hypertension (PAH). Researchers want to see if it's safe and effective when taken with other PAH medicines.
United States · Latvia · South Korea - authorisedTherapeutic confirmatory (Phase III)
68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling SoFAPI study
This study uses a special scan called a PET/CT with a medicine called 68Ga-FAPI to look at the blood vessels in the lungs and the right side of the heart in people with a lung condition called Pulmonary Hypertension. We want to see how these parts change during treatment.
France